The U.S. Food and Drug Administration (FDA) has finalized guidance explaining when it can require cosmetics companies to remove potentially dangerous products from the market. Issued on October 22, 2026, the guidance clarifies the agency’s mandatory recall authority under the Modernization of Cosmetics Regulation Act of 2022 (MoCRA).
For beauty brands, the guidance addresses a practical concern: what happens when the FDA identifies a serious product safety risk and the company does not agree to recall the product voluntarily?
The FDA has historically relied on voluntary recalls for cosmetics. MoCRA gave the agency authority to require recalls under specific circumstances, and the new guidance explains how that process works. The rules have particular consequences for brands that outsource manufacturing, sell through multiple retailers, or rely on third parties to maintain product safety records.
When Can the FDA Require a Cosmetic Product Recall?
The FDA’s final guidance on mandatory cosmetic recalls explains how the agency may exercise its authority under Section 611 of the Federal Food, Drug, and Cosmetic Act. Congress established that authority through MoCRA in 2022, and the FDA first published draft guidance in December 2025. The final version makes no substantive changes to that draft.
The FDA cannot order a mandatory cosmetic recall simply because it disagrees with a company’s labeling or believes a product could be improved. It must determine that there is a reasonable probability that the cosmetic is adulterated or misbranded and that its use or exposure will cause serious adverse health consequences or death.
An adulterated cosmetic may contain harmful substances or have been produced under conditions that make it unsafe. A misbranded cosmetic may have false or misleading labeling or fail to meet applicable labeling requirements. However, these violations alone do not automatically justify a mandatory recall. The FDA must also establish the required level of potential harm.
Before ordering a recall, the agency must give the legally responsible company an opportunity to stop distribution and recall the product voluntarily. If the company refuses, the FDA can order it to cease distribution and notify relevant parties. The company must receive an opportunity for an informal hearing before the agency can proceed with a mandatory recall order under the statutory process.
The distinction between voluntary and mandatory action matters. A company that identifies a problem early may have greater control over how it communicates with retailers, removes affected products, and addresses consumer concerns.
Who Is Responsible When Another Company Manufactures the Cosmetics?
Many beauty brands develop their products through contract manufacturers. The brand controls the product name, packaging, advertising, and customer relationships, while another business handles production, testing, or ingredient sourcing.
Under MoCRA, the “responsible person” is generally the manufacturer, packer, or distributor whose name appears on the cosmetic product’s label. That means a brand can have direct responsibilities under federal law even when another company physically manufactures the product.
Consider a skincare company that sells facial creams under its own trademark but hires a third-party manufacturer to produce them. If testing identifies potentially dangerous contamination, the manufacturer may possess the production records and testing results, while the brand must coordinate with retailers and respond to the FDA.
The brand’s ability to act quickly may depend on the terms of its manufacturing agreement. Contracts should clearly establish who must report safety concerns, provide testing records, investigate defects, notify distributors, and pay recall-related expenses.
These responsibilities are particularly relevant to consumer products manufacturing agreements, where quality-control provisions, indemnification, and access to records can determine how effectively a business responds to a defective product.
A poorly drafted agreement may leave a brand responsible for addressing a recall without timely access to the information needed to identify affected batches. It can also lead to disputes over whether the manufacturer, brand owner, or distributor must absorb the financial losses.
How Cosmetic Recalls Can Lead to Lawsuits and Brand Damage
An FDA recall can create legal problems beyond the immediate removal of products. Consumers may pursue claims involving injuries, retailers may seek reimbursement for unsold inventory, and distributors may dispute responsibility for recall expenses.
The consequences can also extend to advertising. If a company markets a cosmetic as safe, gentle, or suitable for sensitive skin, a product safety investigation may draw attention to whether those representations were adequately supported.
Claims such as “clean,” “non-toxic,” and “natural” already create false advertising concerns for cosmetic brands, particularly when consumers understand those descriptions as promises about product safety. A recall does not automatically make an earlier advertising claim unlawful, but it may provide evidence that consumers or plaintiffs use to challenge the company’s representations.
State laws add another layer of exposure. For example, proposed legislation such as New York’s Beauty Justice Act illustrates how cosmetics safety and ingredient disclosures can become the subject of broader legislative scrutiny and potential litigation.
Brand protection is another concern. When a recall involves only certain batches, inaccurate public notices or unclear product descriptions can cause consumers to believe an entire product line is unsafe. Companies need reliable product identification systems and consistent communications to distinguish affected products from those that remain on the market.
The FDA’s cosmetic recall policy recommends that companies maintain recall plans, appropriate batch identification, and distribution records. Although cosmetic lot numbering is not generally required by federal law, it can help companies identify affected products without unnecessarily recalling unaffected inventory.
The Juris Law Group, P.C. Perspective on Consumer Products Law
The FDA’s guidance reinforces the importance of addressing product safety responsibilities before cosmetics reach consumers. For brands that rely on outside manufacturers, the central concern is whether their contracts and internal procedures allow them to respond promptly when a safety issue arises.
As consumer products attorneys in California, we assess how manufacturing agreements, product labeling, advertising claims, and distribution arrangements affect a company’s legal exposure. A brand may have strong contractual protections against manufacturing defects, but those provisions do not eliminate its independent responsibilities under MoCRA.
Recall planning also intersects with intellectual property rights. Companies should consider how licensing agreements address product quality, trademark use, and the authority to issue public statements about recalled merchandise. Clear licensing and brand protection provisions can help prevent disagreements when several businesses operate under the same brand.
For cosmetics companies, the practical priority is ensuring that contractual responsibilities reflect how products are actually manufactured, tested, marketed, and distributed. A recall is a particularly difficult time to discover that no agreement clearly identifies who controls safety records or communicates with retailers.
What the FDA’s Recall Guidance Means for Beauty Brands in 2027
Over the next 12 months, the FDA’s finalized guidance will provide a clearer procedural framework for cosmetics companies facing serious product safety concerns. Although the document does not create new legal obligations, it explains how the agency intends to use the mandatory recall authority Congress established under MoCRA. Brands should review their recall procedures, manufacturing agreements, and safety documentation against that framework. Companies with extensive retail distribution or multiple contract manufacturers may face greater coordination challenges if a recall becomes necessary.
The broader cosmetics industry should also expect continued attention to product safety, labeling accuracy, and the responsibilities of brand owners under federal and state law. As MoCRA implementation continues, companies that maintain reliable manufacturing records and clearly allocate responsibilities among business partners will be better positioned to respond to safety concerns. The FDA’s guidance makes clear that voluntary cooperation remains the agency’s preferred approach, but mandatory action is available when a company fails to address a qualifying serious health risk.
Common Legal Inquiries
Can the FDA force a cosmetics company to recall a product?
Yes. Under MoCRA, the FDA can require a cosmetic recall when it determines that the product is likely adulterated or misbranded and its use or exposure is reasonably likely to cause serious adverse health consequences or death. The agency must first provide the responsible company an opportunity to recall the product voluntarily.
Who pays for a cosmetic recall when a third-party manufacturer caused the problem?
The answer generally depends on the manufacturing agreement, the circumstances of the defect, and applicable law. A brand may be responsible for coordinating a recall even when another company manufactured the product. Contractual indemnification, insurance coverage, and quality-control provisions can determine how the financial costs are allocated.
Does an FDA cosmetic recall automatically expose a beauty brand to lawsuits?
No. A recall does not automatically establish liability. However, affected consumers, retailers, or distributors may pursue claims based on injuries, misleading representations, or contractual obligations. The outcome depends on the underlying facts, available evidence, and applicable laws.
